NCT06586307Completed
Estimating Lymphocyte Counts from DNA Methylation
Assessment of DNA Methylation Signatures in Lymphocytes for Evaluating the Efficacy and Prognosis of Immunotherapy in Colorectal Cancer
Source: ClinicalTrials.gov · Last updated 19 Sept 2024
Brief summary (registry, in English)
The goal of this observational study is to assess lymphocyte levels in colorectal cancer patients using DNA methylation levels in tissues or blood. The main questions it aims to answer are: Can DNA methylation features calculate lymphocyte levels? Can the calculated lymphocyte levels assess the efficacy and prognosis of immunotherapy?
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 49 (actual)
- First submitted
- 2 Sept 2024
- Start date
- 1 Jan 2023
- Primary completion date
- 1 Jul 2024
- Lead sponsor
- Sixth Affiliated Hospital, Sun Yat-sen University
- Diseases
- Colorectal cancer
- NCT number
- NCT06586307
What you commit to
- Study type: Observational
- Participants enrolled: 49
- From 1 Jan 2023 to the primary completion date, 1 Jul 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Concurrent other malignancies.
- Neoadjuvant immunotherapy not conducted according to the standard protocol.
- Severe adverse chemotherapy reactions that lead to the discontinuation of immunotherapy midway.
- Lack of complete neoadjuvant chemotherapy efficacy assessment data or follow-up data.
- Patients with concurrent other immune system diseases.
Other
- The tissue bank does not store the required whole blood or tissue samples for the experiment.
Who the study is looking for
- Diagnosed with colorectal cancer by colonoscopy pathology and deemed eligible for immunotherapy after assessment.
- Neoadjuvant immunotherapy regimen includes PD-1 or anti-PD-L1.
- R0 resection is performed after neoadjuvant immunotherapy.
- Complete immunotherapy efficacy assessment data and follow-up data are available.
- The tissue bank stores the required whole blood and tissue samples for the experiment.
Age in the registry: 18 years to 80 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| The Sixth Affiliate Hospital of Sun Yat-Sen University Coordinator of this site? Confirm its status | Guangzhou | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.